LITERATURE BASED EVIDENCE OF THE CLINICAL RELEVANCE OFPHARMACOGENETIC TESTING FOR SIMVASTATIN

POSTER PRESENTATIONS

Objective. To determine the strength of evidence present in the published literature for clinical relevance of pharmacogenetic testing for simvastatin Background. Pharmacogenomics or pharmacogenetics according to the FDA “allows one to identify sources of an individual’s profile of drug response and predict the best possible treatment option for this individual.” By analyzing a person’s genetic profile it seems likely that the efficacy of the drug and possible adverse drug reactions can be predicted. This means that based on each patients genetic profile, an individualized treatment plan could be created to maximize optimal outcomes. Pharmacogenetic testing serves to identify the presence of genetic variants which may affect pharmacological outcomes, and allows for the selection of pharmacological therapy based on a patient’s specific genetic make-up and, therefore, has the potential to become an invaluable resource in certain fields of medicine to provide patienttailored pharmacotherapy to patients (Personalized Medicine) Literature evidence pertaining to the clinical relevance of pharmacogenetic testing has historically presented conflicting results and remains a topic of controversy. The strength of evidence pertaining the side effects associated with simvastatin among individuals with different genetic make-up has not been collected yet Methods. A systematic review of literature was conducted using the EMBASE and EBSCO host databases, identifying Cochrane reviews, controlled clinical trials, randomized control trials, meta-analyses and systematic reviews conducted on humans. Only English studies, full-text articles, and those conducted on humans were used included in the search. The search included literature published after 2009. A variety of search terms pertaining to pharmacogenetic testing related to simvastatin including the relevant gene name. Selected articles were evaluated and assigned ratings based on the level of evidence present using JADAD score. A rating of “A” was assigned for high level of evidence, “B” for moderate 62 level of evidence, and “C” for minimal level of evidence Results. The literature search will be presented as the total number of included studies and the results of the literature evaluation with the strength of evidence Conclusion. According to the findings of the literature review, the evidence of clinically relevant pharmacogenetic testing will be presented. Health care providers with be provided with additional information which may enable them to treat patients more efficiently by preventing adverse reactions and anticipating therapeutic responses. The future of pharmacogenetic testing is promising and expected to be welcomed by those whom are concerned with providing optimal pharmaceutical care Grants. NA